These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 30713309)

  • 1. Adrenomedullin: A Novel Therapy for Intractable Crohn's Disease with a Loss of Response to Infliximab.
    Ashizuka S; Kuroishi N; Nakashima K; Inatsu H; Kita T; Kitamura K
    Intern Med; 2019 Jun; 58(11):1573-1576. PubMed ID: 30713309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease.
    Beppu T; Ono Y; Matsui T; Hirai F; Yano Y; Takatsu N; Ninomiya K; Tsurumi K; Sato Y; Takahashi H; Ookado Y; Koga A; Kinjo K; Nagahama T; Hisabe T; Takaki Y; Yao K
    Dig Endosc; 2015 Jan; 27(1):73-81. PubMed ID: 24833527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mucosal healing in different intestinal segments in patients receiving infliximab treatment for small bowel Crohn's disease].
    Zhu ZH; Qiu C; Zhang M; Chen Z; Xiang C; Wang XY
    Nan Fang Yi Ke Da Xue Xue Bao; 2017 Jan; 37(1):44-48. PubMed ID: 28109097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: efficacy of infliximab in Crohn's disease--induction and maintenance of remission.
    Rutgeerts PJ
    Aliment Pharmacol Ther; 1999 Sep; 13 Suppl 4():9-15; discussion 38. PubMed ID: 10597334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
    Colombel JF; Reinisch W; Mantzaris GJ; Kornbluth A; Rutgeerts P; Tang KL; Oortwijn A; Bevelander GS; Cornillie FJ; Sandborn WJ
    Aliment Pharmacol Ther; 2015 Apr; 41(8):734-46. PubMed ID: 25728587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Frequency and possible reasons for the loss of response to biological therapy in Crohn's disease after a one-year treatment period].
    Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Kiss T; Wittmann T
    Orv Hetil; 2011 Jun; 152(24):951-7. PubMed ID: 21609921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
    Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
    Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of infliximab in the treatment of refractory inflammatory bowel disease with complication].
    Lee KM; Kim JS; Shin DH; Cheong JY; Yoo BM; Kim JK; Lee KJ; Hahm KB; Kim JH; Cho SW
    Korean J Gastroenterol; 2004 Nov; 44(5):259-66. PubMed ID: 15564805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological therapy in the management of recent-onset Crohn's disease: why, when and how?
    Löwenberg M; Peppelenbosch M; Hommes D
    Drugs; 2006; 66(11):1431-9. PubMed ID: 16906776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM; Perry CM
    BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying Patients at High Risk of Loss of Response to Infliximab Maintenance Therapy in Paediatric Crohn's Disease.
    Dupont-Lucas C; Sternszus R; Ezri J; Leibovitch S; Gervais F; Amre D; Deslandres C
    J Crohns Colitis; 2016 Jul; 10(7):795-804. PubMed ID: 26822611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab Therapy in Very Early Onset Crohn's Disease: Real-World Experience in China.
    Luo Y; Cheng Q; Fang Y; Yu J; Lou J; Chen J
    Dig Dis Sci; 2021 Oct; 66(10):3555-3562. PubMed ID: 33196961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of Crohn's disease successfully treated with infliximab without steroid].
    Fujise T; Iwakiri R; Tsunada S; Morita H; Kikkawa A; Ootani A; Sakata H; Fujimoto K
    Nihon Shokakibyo Gakkai Zasshi; 2006 Mar; 103(3):295-300. PubMed ID: 16688960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
    Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease.
    Agnholt J; Dahlerup JF; Buntzen S; Tøttrup A; Nielsen SL; Lundorf E
    Aliment Pharmacol Ther; 2003 Mar; 17(5):703-10. PubMed ID: 12641520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
    Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
    Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada.
    Panaccione R;
    Can J Gastroenterol; 2001 Jun; 15(6):371-5. PubMed ID: 11429666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.